Thank you very much.
Mr. Minister, thank you for being here again. It's always a pleasure.
I want to talk a little bit about some numbers we had last week when it came to Medicago and Novavax. You talked about IP protection. We want to protect the IP that came out of these companies. Did we ever get any of the IP from Novavax or from Medicago?